AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10859436
Drug: Alpha-adrenergic receptor
RxNorm normalized name: Alpha-adrenergic receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenergic receptor antagonists (alpha-blockers) including prazosin, alfuzosin, indoramin, terazosin, doxazosin, and tamsulosin.
Trial: 10859436
Drug: Tamsulosin (alpha(1a)-receptor-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (alpha(1a)-receptor-selective blocker).
Trial: 10859436
Drug: Other less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other less selective alpha-blockers.
Trial: 1557677
Drug: Ten weekly
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten weekly sessions of counselling for parents of patients
Trial: 1557677
Drug: Standard after-care
RxNorm normalized name: DIMETHICONE 4 mg in 1 mL TOPICAL CREAM [AFTER CARE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard after-care of medication and support
Trial: 28540870
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg OD
Trial: 26189154
Drug: Combination intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination intervention strategy (CIS) including point‐of‐care CD4 testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention packages, non‐cash financial incentives for linkage and retention.
Trial: 23321216
Drug: Self-administered OGTT
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered OGTT at home (unaided)
Trial: 23321216
Drug: Self-administered OGTT
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered OGTT in clinic (unaided but observed)
Trial: 23321216
Drug: Self-administered OGTT
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered OGTT performed by a nurse with laboratory glucose assays
Trial: 22009649
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (Group A)
Trial: 9543129
Drug: Oral etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral etidronate 400 mg/day for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Trial: 9543129
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months.
Trial: 2724504
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine sulfate (6 mg)
Trial: 31058640
Drug: Test solutions
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solutions
Trial: 24195206
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Wenxin granule (9 g, 3 times a day for 4 weeks)
Trial: 24195206
Drug: Wenxin granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenxin granule alone (9 g, 3 times a day for 4 weeks)
Trial: 22145388
Drug: Ingavirin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingavirin (90 mg once a day)
Trial: 22145388
Drug: Oseltamivir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (150 mg twice a day)
Trial: 16357613
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) with methotrexate (20 mg/week)
Trial: 15612659
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules containing Bifidobacterium, Lactobacillus acidophilus and Enterococcus for 14 days
Trial: 15612659
Drug: Probiotic capsules
RxNorm normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsules containing Bacillus subtilis and Enterococcus faecium for 14 days
Trial: 3789471
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (salbutamol)
Trial: 27459523
Drug: AZD4901 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4901 80 mg/day
Trial: 24899360
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (200 mg capsules containing 65 mg of iron), taken at mealtimes twice daily for one week.
Trial: 24899360
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken at mealtimes twice daily for one week.
Trial: 24899360
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (200 mg capsules containing 65 mg of iron), during the wash-out week.
Trial: 19029275
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (50 mg/kg for 4 days)
Trial: 19029275
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous cyclophosphamide (750 mg/m²)
Trial: 12412870
Drug: Formula supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplemented with docosahexaenoic acid (0.015 g/100 ml) and arachidonic acid (0.031 g/100 ml)
Trial: 6218927
Drug: Mefloquine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 20 mg/kg in children
Trial: 6218927
Drug: Mefloquine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 30 mg/kg in children
Trial: 6218927
Drug: Mefloquine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 750 mg in adults
Trial: 6218927
Drug: Mefloquine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 1000 mg in adults
Trial: 6218927
Drug: Mefloquine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (any dose)
Trial: 23731922
Drug: Intracoronary nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicorandil (4 mg)
Trial: 10550135
Drug: Paclitaxel (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (250 mg/m²) as 24-hour infusion
Trial: 10550135
Drug: FAC (fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (fluorouracil, doxorubicin, and cyclophosphamide in standard doses at every-3-week intervals)
Trial: 7845867
Drug: Chemo-endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-endocrine therapy (orchiectomy and/or diethylstilbestrol diphosphate (DES-DP) plus Cisplatin, with or without other cytotoxic agents)
Trial: 2104073
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 120 mg q.d.s.
Trial: 2104073
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 240 mg b.d.
Trial: 7043713
Drug: Dextropropoxyphene hydrochloride-paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene hydrochloride-paracetamol (Cosalgesic)
Trial: 24180699
Drug: Tramadol 5
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 5 mg/kg
Trial: 24180699
Drug: Tramadol 10
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 10 mg/kg
Trial: 19933175
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 50 mg kg(‐1) for 15 min and then 15 mg kg(‐1) h(‐1) by continuous i.v. infusion until the end of surgery
Trial: 29121334
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg dronabinol
Trial: 7393998
Drug: High-dose Fluphenazine-Decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose Fluphenazine-Decanoate (average dose 225 mg in 14 days)
Trial: 7393998
Drug: Standard-dose Fluphenazine-Decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose Fluphenazine-Decanoate (25 mg in 14 days)
Trial: 7393998
Drug: High-dose Fluphenazine-Decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose Fluphenazine-Decanoate
Trial: 7393998
Drug: Standard-dose Fluphenazine-Decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose Fluphenazine-Decanoate
Trial: 31127468
Drug: Integrated consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated consent model (ICM) with oral consent
Trial: 31127468
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care interventions (including surgical, adjuvant chemotherapy, supportive care, radiology, vascular devices, palliative care, molecular diagnostics)
Trial: 26033220
Drug: neoadjuvant axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neoadjuvant axitinib therapy
Trial: 17472820
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 to 10 mg + Valsartan 160 mg
Trial: 17472820
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 to 20 mg + HCTZ 12.5 mg
Trial: 15262126
Drug: CMC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMC regimen (carboplatin 1500 mg/m², mitoxantrone 75 mg/m², cyclophosphamide 120 mg/kg)
Trial: 15262126
Drug: CTC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC regimen (cisplatin 165 mg/m², thiotepa 600 mg/m², cyclophosphamide 5625 mg/m²)
Trial: 10682563
Drug: Metoprolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol plus routine therapy
Trial: 8565696
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AG and hydroxyprogesterone caproate
Trial: 2474097
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or Enalapril (ACE inhibitors) for 2-6 months
Trial: 2474097
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or Enalapril combined with Mepitiostane (antiestrogenic steroid)
Trial: 105098
Drug: Levamisole therapy
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole therapy
Trial: 28555508
Drug: Conventional 120‐kVp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 120‐kVp scan with a CM volume of 70 ml and an injection rate of 5 ml s‐1 (Group A)
Trial: 28555508
Drug: ssDECT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ssDECT scan with CM volume of 0.6 ml/kg and 40% ASIR (Group B)
Trial: 28555508
Drug: ssDECT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ssDECT scan with CM volume of 0.4 ml/kg and 50% ASIR (Group C)
Trial: 16584285
Drug: Tagamet 400mg
RxNorm normalized name: Tagamet 400mg Tablet
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tagamet 400mg tablet
Trial: 16584285
Drug: 7.5% methacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% methacrylate copolymer cimetidine tablet
Trial: 16584285
Drug: 15% methacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% methacrylate copolymer cimetidine tablet
Trial: 16584285
Drug: 26% methacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26% methacrylate copolymer cimetidine tablet
Trial: 16584285
Drug: Tagamet (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagamet (300 mg/2 mL) intravenous injection
Trial: 12706917
Drug: Eptifibatide 180
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide 180 microg/kg bolus, 2 microg/kg/min infusion, and 180 microg/kg bolus 10 min later (180/2/180) plus half-dose TNK (0.27 mg/kg)
Trial: 12706917
Drug: Standard-dose TNK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose TNK monotherapy (0.53 mg/kg)
Trial: 11097963
Drug: Imipramine (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (180 mg/day)
Trial: 11097963
Drug: Buspirone (38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (38 mg/day)
Trial: 6385868
Drug: Cimetidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (20 mg/kg/day)
Trial: 6385868
Drug: Antacids (Maalox,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (Maalox, 700 mmol (mEq)/1 X 73 m2/day)
Trial: 27893563
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - Usual care and maintenance of daily activities
Trial: 25963053
Drug: Positive post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Positive post-treatment biopsy
Trial: 21622815
Drug: Centrally placed
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally placed polyethylene screw and sheath implant (INTRAFIX)
Trial: 18452437
Drug: Curcuminoids hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids hydrogel patch with squid chitosan (1:1 ratio of curcuminoids microemulsion to polymer solution)
Trial: 18452437
Drug: Curcuminoids hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids hydrogel patch with squid chitosan
Trial: 18452437
Drug: Curcuminoids hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids hydrogel patch
Trial: 16490726
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propacetamol 2 g and ketorolac 30 mg
Trial: 9188930
Drug: 0.05% mequitazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% mequitazine eye-drops, four times daily for 5 days
Trial: 8166477
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by aggressive randomized chemotherapy and PCI
Trial: 8166477
Drug: Preoperative (neoadjuvant)
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative (neoadjuvant) chemotherapy followed by surgery
Trial: 29064536
Drug: No-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-therapy
Trial: 22917554
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (6 μg/breath, 3 to 9 breaths, 4 times/day)
Trial: 17923329
Drug: no-treatment, standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no-treatment, standard care only control
Trial: 15906109
Drug: Cross‐linked hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross‐linked hylan G‐F 20 (group II)
Trial: 9041079
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon alpha 2b (IFN‐alpha) 5 x 10(6) IU/ml, four times daily for 4 weeks
Trial: 9041079
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon alpha 2b (IFN‐alpha) for patients with correction > 5.00 D
Trial: 9041079
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon alpha 2b (IFN‐alpha)
Trial: 1552999
Drug: Intravenous 1-alpha-hydroxyvitamin
RxNorm normalized name: 1α-hydroxyvitamin D2
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) after each dialysis at increasing doses up to 4 micrograms, with Mg(OH)2 as sole phosphate binder.
Trial: 1552999
Drug: Intravenous 1-alpha-hydroxyvitamin
RxNorm normalized name: 1α-hydroxyvitamin D2
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 1-alpha-hydroxyvitamin D3 (1 alpha‐OH‐D3) with Mg(OH)2 as sole phosphate binder.
Trial: 3991397
Drug: Diumide K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diumide K (frusemide 40 mg, potassium 8 mmol)
Trial: 3991397
Drug: Burinex K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burinex K (bumetanide 0.5 mg, potassium 7.7 mmol)
Trial: 22268900
Drug: Semantic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic therapy (two 15-min sessions per week for 8 weeks) targeting words from semantic categories (animals, food, clothes)
Trial: 22268900
Drug: Waiting control
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting control group (no therapy in Phase 1)
Trial: 22268900
Drug: Combined effect
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined effect of therapy over the two groups
Trial: 22268900
Drug: Pre-therapy TAWF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-therapy TAWF scores
Trial: 22268900
Drug: Post-therapy TAWF
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-therapy TAWF scores
Trial: 7562730
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent neutral NaF solution rinsed once a week
Trial: 7562730
Drug: 2.2 mg
RxNorm normalized name: menthol 2.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 mg NaF tablet chewed, rinsed, and swallowed daily
Trial: 7562730
Drug: Both procedures
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both procedures (mouthrinse and tablet)
Trial: 31341122
Drug: Dental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatment (DT) perceived as a cause of OMLs
Trial: 31341122
Drug: Chief complaint
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chief complaint site (CC)
Trial: 20374670
Drug: Behavioral activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral activation therapy, provided weekly for 4 months followed by monthly sessions for 4 months.
Trial: 17493183
Drug: Cefepime 1
RxNorm normalized name: cefepime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 1 g intramuscularly every 24 hours
Trial: 17493183
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g intramuscularly every 24 hours
Trial: 2248837
Drug: Diclofenac 1
RxNorm normalized name: diclofenac 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1 mg kg‐1 i.m.
Trial: 2248837
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic (placebo)
Trial: 24193288
Drug: Absorbable fibrin
RxNorm normalized name: TachoSil Absorbable Fibrin Sealant Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable fibrin sealant patch (AFSP)
Trial: 24193288
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment (ST)
Trial: 24193288
Drug: Absorbable fibrin
RxNorm normalized name: TachoSil Absorbable Fibrin Sealant Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorbable fibrin sealant patch (AFSP) and Standard surgical treatment (ST)
Trial: 19214861
Drug: 1064 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064 nm Nd:YAG laser treatment (fluence 30 J/cm, 18 mm spot size, dynamic cooling device pulse duration of 30 ms)
Trial: 11913309
Drug: AHDC chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHDC chewing gum (5% sodium bicarbonate), 2 tablets for 20 minutes, 2 times daily
Trial: 11913309
Drug: Mint tablet
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mint tablet (sugarless), 2 tablets for 20 minutes, 2 times daily
Trial: 7701191
Drug: Modafinil (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (300 mg daily)
Trial: 3588258
Drug: Adjuvant oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant oxygen therapy for 48 hours